Examining How Antiphospholipid Antibodies Activate Intracellular Signaling Pathways: A Systematic Review

Seminars in Arthritis and Rheumatism

Volumn 41, Issue 5, 2012, Pages 720-736

  Poulton, Katie ^a   Rahman, Anisur ^a   Giles, Ian ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antiphospholipid syndrome; Nuclear factor kappa B; Protein kinase; Toll like receptor

Indexed keywords

CELL SURFACE RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOLIPID ANTIBODY; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CELL TYPE; ENDOMETRIUM CELL; ENDOTHELIUM CELL; FIBROBLAST; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MONOCYTE; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; THROMBOCYTE; TROPHOBLAST; UPREGULATION;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; CELLS, CULTURED; HUMANS; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84859420078     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2011.09.004     Document Type: Article

References (49)

1. Khamashta M.A., Cuadrado M.J., Mujic F., Taub N.A., Hunt B.J., Hughes G.R. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995, 332(15):993-997.
2. RuizIrastorza G., Hunt B.J., Khamashta M.A. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007, 57(8):1487-1495.
3. Derksen R.H., de Groot P.G. The obstetric antiphospholipid syndrome. J Reprod Immunol 2008, 77(1):41-50.
4. LopezPedrera C., Buendia P., Cuadrado M.J., Siendones E., Aguirre M.A., Barbarroja N., et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NFkappaB/Rel proteins via the p38 mitogenactivated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006, 54(1):301-311.
5. Pierangeli S.S., Colden-Stanfield M., Liu X., Barker J.H., Anderson G.L., Harris E.N. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999, 99(15):1997-2002.
6. Vega-Ostertag M., Harris E.N., Pierangeli S.S. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 2004, 50(9):2911-2919.
7. Mulla M.J., Brosens J.J., Chamley L.W., Giles I., Pericleous C., Rahman A., et al. Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway. Am J Reprod Immunol 2009, 62(2):96-111.
8. Di Simone N., Di Nicuolo F., D'Ippolito S., Castellani R., Tersigni C., Caruso A., et al. Antiphospholipid antibodies affect human endometrial angiogenesis. Biol Reprod 2010, 83(2):212-219.
9. Chen P.P., Giles I. Antibodies to serine proteases in the antiphospholipid syndrome. Curr Rheumatol Rep 2010, 12(1):45-52.
10. Redecha P., Tilley R., Tencati M., Salmon J.E., Kirchhofer D., Mackman N., et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007, 110(7):2423-2431.
11. Redecha P., Franzke C.W., Ruf W., Mackman N., Girardi G. Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest 2008, 118(10):3453-3461.
12. Tsutsumi A., Matsuura E., Ichikawa K., Fujisaku A., Mukai M., Kobayashi S., et al. Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996, 39(9):1466-1474.
13. Giannakopoulos B., Passam F., Rahgozar S., Krilis S.A. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 2007, 109(2):422-430.
14. Zhang J., McCrae K.R. Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood 2005, 105(5):1964-1969.
15. van Lummel M., Pennings M.T., Derksen R.H., Urbanus R.T., Lutters B.C., Kaldenhoven N., et al. The binding site in {beta}2-glycoprotein I for ApoER2[prime] on platelets is located in domain V. J Biol Chem 2005, 280(44):36729-36736.
16. Raschi E., Testoni C., Bosisio D., Borghi M.O., Koike T., Mantovani A., et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003, 101(9):3495-3500.
17. Vega-Ostertag M., Casper K., Swerlick R., Ferrara D., Harris E.N., Pierangeli S.S. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005, 52(5):1545-1554.
18. Pierangeli S.S., Vega-Ostertag M.E., Raschi E., Liu X., Romay-Penabad Z., De Micheli V., et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis 2007, 66(10):1327-1333.
19. Tzang B.S., Tsai C.C., Chiu C.C., Shi J.Y., Hsu T.C. Up-regulation of adhesion molecule expression and induction of TNF-alpha on vascular endothelial cells by antibody against human parvovirus B19 VP1 unique region protein. Clin Chim Acta 2008, 395(1-2):77-83.
20. Meroni P.L., Raschi E., Testoni C., Tincani A., Balestrieri G., Molteni R., et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001, 44(12):2870-2878.
21. Lambrianides A., Carroll C.J., Pierangeli S.S., Pericleous C., Branch W., Rice J., et al. Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. J Immunol 2010, 184(12):6622-6628.
22. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gotzsche P.C., Ioannidis J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339:b2700.
23. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4(2):295-306.
24. Zhou H., Yan Y., Xu G., Zhou B., Wen H., Guo D., et al. Toll-like receptor (TLR)-4 mediates anti-beta2GPI/beta2GPI-induced tissue factor expression in THP-1 cells. Clin Exp Immunol 2011, 163(2):189-198.
25. Sorice M., Longo A., Capozzi A., Garofalo T., Misasi R., Alessandri C., et al. Anti-beta(2)-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007, 56(8):2687-2697.
26. Satta N., Kruithof E.K., Fickentscher C., Dunoyer-Geindre S., Boehlen F., Reber G., et al. Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies. Blood 2011, 117(20):5523-5531.
27. Satta N., Dunoyer-Geindre S., Reber G., Fish R.J., Boehlen F., Kruithof E.K., et al. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood 2007, 109(4):1507-1514.
28. Doring Y., Hurst J., Lorenz M., Prinz N., Clemens N., Drechsler M.D., et al. Human antiphospholipid antibodies induce TNFalpha in monocytes via Toll-like receptor 8. Immunobiology 2010, 215(3):230-241.
29. Hurst J., Prinz N., Lorenz M., Bauer S., Chapman J., Lackner K.J., et al. TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells. Immunobiology 2009, 214(8):683-691.
30. Vega-Ostertag M.E., Ferrara D.E., Romay-Penabad Z., Liu X., Taylor W.R., Colden-Stanfield M., et al. Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. J Thromb Haemost 2007, 5(9):1828-1834.
31. Simoncini S., Sapet C., Camoin-Jau L., Bardin N., Harle J.R., Sampol J., et al. Role of reactive oxygen species and p38 MAPK in the induction of the pro-adhesive endothelial state mediated by IgG from patients with anti-phospholipid syndrome. Int Immunol 2005, 17(4):489-500.
32. Aronovich R., Gurwitz D., Kloog Y., Chapman J. Antiphospholipid antibodies, thrombin and LPS activate brain endothelial cells and Ras-dependent pathways through distinct mechanisms. Immunobiology 2005, 210(10):781-788.
33. Bohgaki M., Atsumi T., Yamashita Y., Yasuda S., Sakai Y., Furusaki A., et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies. Int Immunol 2004, 16(11):1633-1641.
34. Bohgaki M., Matsumoto M., Atsumi T., Kondo T., Yasuda S., Horita T., et al. Plasma gelsolin facilitates interaction between beta2 glycoprotein I and alpha5beta1 integrin. J Cell Mol Med 2011, 15(1):141-151.
35. Cuadrado M.J., Buendia P., Velasco F., Aguirre M.A., Barbarroja N., Torres L.A., et al. Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. J Thromb Haemost 2006, 4(11):2461-2469.
36. Lopez-Pedrera C., Ruiz-Limon P., Aguirre M.A., Barbarroja N., Perez-Sanchez C., Buendia P., et al. Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Ann Rheum Dis 2011, 70(4):675-682.
37. Sikara M.P., Routsias J.G., Samiotaki M., Panayotou G., Moutsopoulos H.M., Vlachoyiannopoulos P.G. {beta}2 Glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome. Blood 2010, 115(3):713-723.
38. Shi T., Giannakopoulos B., Yan X., Yu P., Berndt M.C., Andrews R.K., et al. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum 2006, 54(8):2558-2567.
39. Espinola R.G., Liu X., Colden-Stanfield M., Hall J., Harris E.N., Pierangeli S.S. E-Selectin mediates pathogenic effects of antiphospholipid antibodies. J Thromb Haemost 2003, 1(4):843-848.
40. Ortona E., Capozzi A., Colasanti T., Conti F., Alessandri C., Longo A., et al. Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome. Blood 2010, 116(16):2960-2967.
41. Montiel-Manzano G., Romay-Penabad Z., Papalardo de Martinez E., Meillon-Garcia L.A., Garcia-Latorre E., Reyes-Maldonado E., et al. in vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies. Ann NY Acad Sci 2007, 1108:540-553.
42. Dunoyer-Geindre S., de Moerloose P., Galve-de Rochemonteix B., Reber G., Kruithof E.K. NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies. Thromb Haemost 2002, 88(5):851-857.
43. Pierangeli S.S., Liu X., Espinola R., Olee T., Zhu M., Harris N.E., et al. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost 2000, 84(3):388-395.
44. Giles I., Pericleous C., Liu X., Ehsanullah J., Clarke L., Brogan P., et al. Thrombin binding predicts the effects of sequence changes in a human monoclonal antiphospholipid antibody on its in vivo biologic actions. J Immunol 2009, 182(8):4836-4843.
45. Alard J.E., Gaillard F., Daridon C., Shoenfeld Y., Jamin C., Youinou P. TLR2 is one of the endothelial receptors for beta 2-glycoprotein I. J Immunol 2010, 185(3):1550-1557.
46. Bernales I., Fullaondo A., Marin-Vidalled M.J., Ucar E., Martinez-Taboada V., Lopez-Hoyos M., et al. Innate immune response gene expression profiles characterize primary antiphospholipid syndrome. Genes Immun 2008, 9(1):38-46.
47. López-Pedrera C., Cuadrado M., Herández V., Buendïa P., Aguirre M., Barbarroja N., et al. Proteomic analysis in monocytes of antiphospholipid syndrome patients: Deregulation of proteins related to the development of thrombosis. Arthritis Rheum 2008, 58(9):2835-2844.
48. Genovese M.C. Inhibition of p38: has the fat lady sung?. Arthritis Rheum 2009, 60(2):317-320.
49. Cohen S.B., Cheng T.T., Chindalore V., Damjanov N., Burgos-Vargas R., Delora P., et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009, 60(2):335-344.